Ketamine and Slow-Wave Sleep in Treatment-Resistant Depression

Most conversations about depression and sleep stop at the obvious: people who are depressed often sleep badly. A 2026 study in Neuropsychopharmacology points somewhere deeper. It suggests that part of why ketamine therapy can lift depression so quickly may happen during the first stretch of deep sleep after a dose.

The study looked at a brain-sleep signal called slow-wave activity, and found that ketamine restored it in people with treatment-resistant depression who responded to the medicine. That matters because slow-wave activity is one of the brain’s repair signals, and it tends to run low in depression. If you or someone you love is weighing ketamine therapy, this research offers a clearer picture of what may be happening in mood and in sleep at the same time.

What slow-wave activity is, and why it matters in depression

Slow-wave activity (SWA) is the deep, slow electrical rhythm your brain produces during the most restorative stage of sleep. According to the Laboratory for the Study of Sleep Slow-wave Activity at the University of Pennsylvania, SWA is the power in the delta frequency band, roughly 0.5 to 3.9 cycles per second, and it serves as a marker of how much sleep your brain needs. It runs high at the start of the night and tapers as the night goes on.

This deep sleep does real work. It supports memory, immune function, and neuroplasticity, the brain’s ability to form and reshape connections between neurons. The same lab notes that SWA naturally declines as we age, and that it is reduced in several conditions, including major depressive disorder.

That last point is worth sitting with. People living with depression often carry a quieter version of this repair signal. If deep sleep is when the brain does some of its rebuilding, a weakened slow-wave rhythm may be one reason depression can feel so stuck.

What the 2026 ketamine study found

The study, “Modulation of early non-rapid eye movement slow wave activity by ketamine in treatment-resistant depression,” published in Neuropsychopharmacology, compared a single dose of ketamine against a placebo. Researchers measured slow-wave activity during the first period of non-rapid eye movement sleep, often shortened to NREM1, the early deep-sleep window soon after a person falls asleep.

The sample was larger than most sleep studies in this area: 91 adults with treatment-resistant depression (TRD), meaning depression that has not eased after standard treatments, alongside 42 healthy volunteers as a comparison group. A few findings stand out:

  • At the start, the depression group had lower early-sleep SWA than the healthy volunteers, matching the broader pattern of weakened deep-sleep signals in depression.
  • Ketamine raised NREM1 slow-wave activity in the depression group, but placebo did not. The increase was clearest in the people who responded to ketamine.
  • Ketamine had no such effect in the healthy volunteers. Their sleep signal was not running low to begin with, so there was less to restore.
  • The effect faded with age. Among the depression group, older participants saw smaller increases in slow-wave activity after ketamine.

The pattern is telling. Ketamine did not flood every brain with extra deep-sleep activity. It lifted the signal where it was depleted, and most in the people whose mood improved.

Ketamine also improved overall sleep, not only the deep-sleep signal

Beyond the slow-wave measure, the depression group slept better after ketamine. According to the study, participants with treatment-resistant depression showed:

  • More total sleep time
  • Higher sleep efficiency, meaning more of their time in bed was actually spent asleep
  • Shorter sleep latency, meaning they fell asleep faster

These are practical changes, the kind a person might actually notice the next morning. Read alongside the slow-wave finding, they suggest ketamine may support both the quality of deep sleep and the experience of sleeping through the night, at least in the short window the study measured.

A word of caution belongs here. The study tracked sleep in the period right after dosing, so it speaks to early effects rather than months of follow-up. The researchers themselves frame slow-wave activity as a possible window into how ketamine works, not a settled explanation.

Why this points toward sleep-based repair

The researchers connect their findings to a longer-standing idea: that ketamine’s rapid antidepressant effects may run partly through sleep and brain plasticity. In the study’s own discussion, the authors describe the increase in early slow-wave activity among responders as a sign of partial normalization of sleep homeostasis, the body’s system for balancing sleep need, and a possible restoration of the neural connectivity that healthy deep sleep depends on.

This fits a two-stage model of how rapid antidepressants may work: a fast shift in how brain networks fire, followed by a slower rewiring of connections over the following days. Under that view, the bump in deep-sleep activity reads less like a side effect and more like a sign of the brain beginning to repair itself. For a fuller picture of that rewiring process, see our explainer on how IV ketamine works in the brain and our glossary entry on neuroplasticity.

The age finding adds a quieter, honest note. If sleep-dependent plasticity weakens over a lifetime, the same medicine may move the deep-sleep signal less in an older brain. That does not mean ketamine cannot help at any age. It means the mechanism may work differently across the lifespan, which is the kind of detail careful research is meant to surface.

What this means if you are considering ketamine therapy

For members weighing their options, this study reinforces something we hold closely: ketamine works as a catalyst, and rest is part of how that catalyst does its job. If deep sleep is one of the pathways through which ketamine supports recovery, protecting your sleep around treatment is part of the care, not an afterthought.

A few grounded takeaways:

  • Treat sleep as a partner to the medicine. Building steadier sleep habits during a course of treatment may help the brain do its repair work. We explore this further in our piece on sleep optimization and ketamine therapy.
  • Setting and supervision shape the experience. This study used carefully measured, single doses in a controlled research environment. In clinical care, intravenous (IV) ketamine, ketamine delivered slowly into a vein under medical monitoring, gives clinicians precise control over dose and pacing. You can read more in our comparison of IV and intramuscular ketamine.
  • Preparation and integration carry the change forward. The medicine may open a window. What you do with it, through reflection, support, and gentle routines like protected sleep, helps a short-term shift settle into something more durable.

This is one study, and it measures a signal rather than a cure. It does not promise an outcome for any one person. What it offers is a clearer understanding of why ketamine can act so quickly, and a reminder that recovery involves the whole nervous system, including the hours you spend asleep.

If you are curious whether medically supervised ketamine therapy might fit your situation, the clearest next step is a conversation with clinicians who can review your history and screen for safety. Speak with our care team to explore what a thoughtful, supervised path could look like for you.

FAQs

What is slow-wave activity, and how is it related to depression?

Slow-wave activity is the deep, slow brain rhythm produced during the most restorative stage of sleep, measured in the delta frequency band of roughly 0.5 to 3.9 cycles per second. It is considered a marker of the brain’s sleep need and is tied to neuroplasticity, the brain’s ability to reshape its connections. Research from the University of Pennsylvania’s slow-wave sleep lab notes that this activity is reduced in major depressive disorder, which is one reason scientists study it as a possible window into how depression affects the brain.

Does ketamine improve sleep in people with treatment-resistant depression?

In the 2026 Neuropsychopharmacology study, adults with treatment-resistant depression showed more total sleep time, higher sleep efficiency, and faster sleep onset after a single ketamine infusion, while a placebo group did not. The same group also showed increased slow-wave activity during early deep sleep, especially among those whose mood improved. These were short-term effects measured soon after dosing, so they describe early changes rather than long-term sleep outcomes.

Why did ketamine raise slow-wave activity in depressed patients but not in healthy volunteers?

In the study, the healthy volunteers already had typical levels of early-sleep slow-wave activity, so there was little to restore. The participants with treatment-resistant depression started with lower slow-wave activity, and ketamine lifted the signal where it was depleted. This selective effect is part of why the researchers describe ketamine’s action as a possible partial normalization of disrupted sleep regulation rather than a general boost to everyone’s deep sleep.

Does age affect how ketamine influences deep sleep?

The study found that the ketamine-related increase in early slow-wave activity grew smaller with advancing age among participants with treatment-resistant depression. The researchers suggest that sleep-dependent plasticity, the brain’s capacity to repair and reshape connections during deep sleep, may diminish over the lifespan. This does not mean ketamine is ineffective for older adults; it suggests the underlying sleep mechanism may work differently with age.

Is IV ketamine better than other forms for depression?

Each route of administration has trade-offs, and the right choice depends on a person’s history and clinical needs. Intravenous (IV) ketamine, delivered slowly into a vein under medical monitoring, lets clinicians control the dose and pacing precisely, which is why it is often used in carefully supervised settings. Other forms, such as intramuscular or intranasal ketamine, can be less predictable. A consultation with a qualified clinician is the best way to understand which approach may suit you.

Nushama

Discover What Psychedelic Medicine Can Do for You

To transcend depression, anxiety, alcohol use disorders, and trauma-induced mood disorders, Nushama offers IV ketamine for an ego-dissolving psychedelic experience. A holistic path of mindful intention setting, ketamine journeys, and thoughtful integration in safe, healing-focused settings empower members to reset and reconnect.

Explore Our Blog